Plasma Protein Binding of Direct Oral Anticoagulants

Introduction to Plasma Protein Binding

Apixaban, rivaroxaban, and edoxaban have significant plasma protein binding, with apixaban and rivaroxaban being extensively bound (>90%) and edoxaban moderately bound (55%) to plasma proteins 1, 2

Apixaban is highly bound to plasma proteins (92-94%), which contributes to its pharmacokinetic profile with a half-life of approximately 12 hours 2, 3
Rivaroxaban is extensively bound to plasma proteins (92-95%), which classifies it as a low-clearance drug despite its relatively shorter half-life of 5-9 hours in healthy adults 1, 4
Edoxaban is moderately bound to plasma proteins (55%), which is significantly lower than the other factor Xa inhibitors 2, 5

Protein binding affects the drugs' clearance mechanisms, with varying degrees of renal elimination: rivaroxaban (66%), edoxaban (50%), and apixaban (27%) 6
The high protein binding of apixaban and rivaroxaban makes them non-dialyzable, unlike dabigatran which has lower protein binding (35%) and can be removed by dialysis 6, 7

In patients with hypoalbuminemia, the pharmacokinetics of these highly protein-bound drugs may be significantly altered, potentially affecting their half-lives and anticoagulant effects 3, 8

The high protein binding of apixaban and rivaroxaban may contribute to potential drug interactions when co-administered with other highly protein-bound medications 1, 2
Displacement from protein binding sites can increase the free (active) fraction of these drugs, potentially increasing their anticoagulant effects 2

The high protein binding of apixaban and rivaroxaban contributes to their accumulation risk in patients with hepatic impairment 1, 4
Rivaroxaban absorption is significantly increased when taken with food, and manufacturer recommendations suggest taking doses of 15-20 mg with the largest meal of the day to increase bioavailability 1
Edoxaban's lower protein binding (55%) may result in different pharmacokinetic behavior compared to the more highly protein-bound factor Xa inhibitors 2, 5